A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers

Anthony Tolcher, Keith Flaherty, Geoffrey I. Shapiro, Jordan Berlin, Thomas Elmer Witzig, Thomas Matthew Habermann, Andrea Bullock, Edwin Rock, Agnes Elekes, Chester Lin, Dusan Kostic, Naoto Ohi, Drew Rasco, Kyriakos P. Papadopoulos, Amita Patnaik, Lon Smith, Gregory M. Cote

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Lessons Learned: OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation that exhibited promising anticancer activity in preclinical models. In this first-in-human phase I study of OPB-111077 in unselected advanced cancers, treatment-emergent adverse events, most frequently nausea, fatigue, and vomiting, were generally mild to moderate in intensity and could be medically managed. Overall, only modest clinical activity was observed after OPB-111077 given as monotherapy. Notable antitumor activity was seen in a subject with diffuse large B-cell lymphoma. Background: OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation with promising anticancer activity in preclinical models. Methods: Open-label, phase I trial of OPB-111077 in advanced cancers with no available therapy of documented benefit. Initial dose escalation in unselected subjects was followed by dose expansion. Patients received oral OPB-111077 daily in 28-day cycles until loss of clinical benefit. Results: Eighteen subjects enrolled in dose escalation, and 127 in dose expansion. Dose-limiting toxicities were observed at 300 mg and 400 mg QD; maximum tolerated dose was defined as 250 mg QD. Frequently reported treatment-emergent adverse events (TEAEs) included nausea, fatigue, and vomiting. TEAEs were generally mild to moderate and could be medically managed. OPB-111077 reached micromolar drug concentrations, had an elimination half-life of approximately 1 day, and reached steady-state by day 8. A durable partial response was observed in one subject with diffuse large B-cell lymphoma. Seven subjects with diverse tumor types had stable disease or minor responses for at least eight treatment cycles (224 days). Conclusion: OPB-111077 is generally well tolerated, and its pharmacokinetic profile is sufficient for further clinical development. Notable clinical activity was observed in a subject with diffuse large B-cell lymphoma. Overall, modest efficacy was observed against unselected tumors.

Original languageEnglish (US)
Pages (from-to)658-e72
JournalOncologist
Volume23
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Oxidative Phosphorylation
Lymphoma, Large B-Cell, Diffuse
Neoplasms
Nausea
Vomiting
Fatigue
Therapeutics
Maximum Tolerated Dose
Half-Life
Pharmacokinetics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers. / Tolcher, Anthony; Flaherty, Keith; Shapiro, Geoffrey I.; Berlin, Jordan; Witzig, Thomas Elmer; Habermann, Thomas Matthew; Bullock, Andrea; Rock, Edwin; Elekes, Agnes; Lin, Chester; Kostic, Dusan; Ohi, Naoto; Rasco, Drew; Papadopoulos, Kyriakos P.; Patnaik, Amita; Smith, Lon; Cote, Gregory M.

In: Oncologist, Vol. 23, No. 6, 01.06.2018, p. 658-e72.

Research output: Contribution to journalArticle

Tolcher, A, Flaherty, K, Shapiro, GI, Berlin, J, Witzig, TE, Habermann, TM, Bullock, A, Rock, E, Elekes, A, Lin, C, Kostic, D, Ohi, N, Rasco, D, Papadopoulos, KP, Patnaik, A, Smith, L & Cote, GM 2018, 'A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers', Oncologist, vol. 23, no. 6, pp. 658-e72. https://doi.org/10.1634/theoncologist.2017-0325
Tolcher, Anthony ; Flaherty, Keith ; Shapiro, Geoffrey I. ; Berlin, Jordan ; Witzig, Thomas Elmer ; Habermann, Thomas Matthew ; Bullock, Andrea ; Rock, Edwin ; Elekes, Agnes ; Lin, Chester ; Kostic, Dusan ; Ohi, Naoto ; Rasco, Drew ; Papadopoulos, Kyriakos P. ; Patnaik, Amita ; Smith, Lon ; Cote, Gregory M. / A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers. In: Oncologist. 2018 ; Vol. 23, No. 6. pp. 658-e72.
@article{19aa2650f27e4db598bb872954f24a4b,
title = "A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers",
abstract = "Lessons Learned: OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation that exhibited promising anticancer activity in preclinical models. In this first-in-human phase I study of OPB-111077 in unselected advanced cancers, treatment-emergent adverse events, most frequently nausea, fatigue, and vomiting, were generally mild to moderate in intensity and could be medically managed. Overall, only modest clinical activity was observed after OPB-111077 given as monotherapy. Notable antitumor activity was seen in a subject with diffuse large B-cell lymphoma. Background: OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation with promising anticancer activity in preclinical models. Methods: Open-label, phase I trial of OPB-111077 in advanced cancers with no available therapy of documented benefit. Initial dose escalation in unselected subjects was followed by dose expansion. Patients received oral OPB-111077 daily in 28-day cycles until loss of clinical benefit. Results: Eighteen subjects enrolled in dose escalation, and 127 in dose expansion. Dose-limiting toxicities were observed at 300 mg and 400 mg QD; maximum tolerated dose was defined as 250 mg QD. Frequently reported treatment-emergent adverse events (TEAEs) included nausea, fatigue, and vomiting. TEAEs were generally mild to moderate and could be medically managed. OPB-111077 reached micromolar drug concentrations, had an elimination half-life of approximately 1 day, and reached steady-state by day 8. A durable partial response was observed in one subject with diffuse large B-cell lymphoma. Seven subjects with diverse tumor types had stable disease or minor responses for at least eight treatment cycles (224 days). Conclusion: OPB-111077 is generally well tolerated, and its pharmacokinetic profile is sufficient for further clinical development. Notable clinical activity was observed in a subject with diffuse large B-cell lymphoma. Overall, modest efficacy was observed against unselected tumors.",
author = "Anthony Tolcher and Keith Flaherty and Shapiro, {Geoffrey I.} and Jordan Berlin and Witzig, {Thomas Elmer} and Habermann, {Thomas Matthew} and Andrea Bullock and Edwin Rock and Agnes Elekes and Chester Lin and Dusan Kostic and Naoto Ohi and Drew Rasco and Papadopoulos, {Kyriakos P.} and Amita Patnaik and Lon Smith and Cote, {Gregory M.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1634/theoncologist.2017-0325",
language = "English (US)",
volume = "23",
pages = "658--e72",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "6",

}

TY - JOUR

T1 - A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers

AU - Tolcher, Anthony

AU - Flaherty, Keith

AU - Shapiro, Geoffrey I.

AU - Berlin, Jordan

AU - Witzig, Thomas Elmer

AU - Habermann, Thomas Matthew

AU - Bullock, Andrea

AU - Rock, Edwin

AU - Elekes, Agnes

AU - Lin, Chester

AU - Kostic, Dusan

AU - Ohi, Naoto

AU - Rasco, Drew

AU - Papadopoulos, Kyriakos P.

AU - Patnaik, Amita

AU - Smith, Lon

AU - Cote, Gregory M.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Lessons Learned: OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation that exhibited promising anticancer activity in preclinical models. In this first-in-human phase I study of OPB-111077 in unselected advanced cancers, treatment-emergent adverse events, most frequently nausea, fatigue, and vomiting, were generally mild to moderate in intensity and could be medically managed. Overall, only modest clinical activity was observed after OPB-111077 given as monotherapy. Notable antitumor activity was seen in a subject with diffuse large B-cell lymphoma. Background: OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation with promising anticancer activity in preclinical models. Methods: Open-label, phase I trial of OPB-111077 in advanced cancers with no available therapy of documented benefit. Initial dose escalation in unselected subjects was followed by dose expansion. Patients received oral OPB-111077 daily in 28-day cycles until loss of clinical benefit. Results: Eighteen subjects enrolled in dose escalation, and 127 in dose expansion. Dose-limiting toxicities were observed at 300 mg and 400 mg QD; maximum tolerated dose was defined as 250 mg QD. Frequently reported treatment-emergent adverse events (TEAEs) included nausea, fatigue, and vomiting. TEAEs were generally mild to moderate and could be medically managed. OPB-111077 reached micromolar drug concentrations, had an elimination half-life of approximately 1 day, and reached steady-state by day 8. A durable partial response was observed in one subject with diffuse large B-cell lymphoma. Seven subjects with diverse tumor types had stable disease or minor responses for at least eight treatment cycles (224 days). Conclusion: OPB-111077 is generally well tolerated, and its pharmacokinetic profile is sufficient for further clinical development. Notable clinical activity was observed in a subject with diffuse large B-cell lymphoma. Overall, modest efficacy was observed against unselected tumors.

AB - Lessons Learned: OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation that exhibited promising anticancer activity in preclinical models. In this first-in-human phase I study of OPB-111077 in unselected advanced cancers, treatment-emergent adverse events, most frequently nausea, fatigue, and vomiting, were generally mild to moderate in intensity and could be medically managed. Overall, only modest clinical activity was observed after OPB-111077 given as monotherapy. Notable antitumor activity was seen in a subject with diffuse large B-cell lymphoma. Background: OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation with promising anticancer activity in preclinical models. Methods: Open-label, phase I trial of OPB-111077 in advanced cancers with no available therapy of documented benefit. Initial dose escalation in unselected subjects was followed by dose expansion. Patients received oral OPB-111077 daily in 28-day cycles until loss of clinical benefit. Results: Eighteen subjects enrolled in dose escalation, and 127 in dose expansion. Dose-limiting toxicities were observed at 300 mg and 400 mg QD; maximum tolerated dose was defined as 250 mg QD. Frequently reported treatment-emergent adverse events (TEAEs) included nausea, fatigue, and vomiting. TEAEs were generally mild to moderate and could be medically managed. OPB-111077 reached micromolar drug concentrations, had an elimination half-life of approximately 1 day, and reached steady-state by day 8. A durable partial response was observed in one subject with diffuse large B-cell lymphoma. Seven subjects with diverse tumor types had stable disease or minor responses for at least eight treatment cycles (224 days). Conclusion: OPB-111077 is generally well tolerated, and its pharmacokinetic profile is sufficient for further clinical development. Notable clinical activity was observed in a subject with diffuse large B-cell lymphoma. Overall, modest efficacy was observed against unselected tumors.

UR - http://www.scopus.com/inward/record.url?scp=85048851637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048851637&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2017-0325

DO - 10.1634/theoncologist.2017-0325

M3 - Article

C2 - 29511132

AN - SCOPUS:85048851637

VL - 23

SP - 658-e72

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 6

ER -